Carolina Saldana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carolina Saldana has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Frédéric Rolland
Institut de Cancérologie de L'ouest, Site René Gauducheau, Saint Herblain, France
3 shared publications Aude Fléchon
Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France
2 shared publicationsBrigitte Laguerre
Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France
2 shared publicationsChristine Chevreau
Department of Medical Oncology, ICR-IUCT Oncopole, Toulouse, France
2 shared publicationsGuilhem Roubaud
Department of Medical Oncology, Institut Bergonie, Bordeaux, France
2 shared publicationsGwenaelle Gravis
Department of Medical Oncology, Paoli-Calmette Institute, Marseille, France
2 shared publications
Latest Publications
- 8 September 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 175, 43-53
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
- 8 September 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 175, 43-53
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
- 1 December 2021
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 19 (6) , 554-562
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial
- 1 December 2021
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 19 (6) , 554-562
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 4561
Metastatic chromophobe renal cell carcinoma treated with target therapies: A Renal Cross Chanel Group (RCCG) study.
4561 Background: Metastatic Chromophobe renal cell carcinoma (mChRCC) is a rare entity with no specific targeted therapy recommended. We aim to assess the outcome of targeted therapy (TT) in a large cohort of mChRCC patients (pts). Methods: RCCG collected data from 27 centers in France, UK and Italy. Patients’ characteristics, treatments, best response and outcomes were collected. Time to treatment failure (TTF) for first-line treatment was calculated from the initiation of first-line treatment (t0) until failure (progression disease, toxicity, death). Overall survival (OS [95%CI]) was calculated from t0 until death. Survival outcomes were described using Kaplan-Meier method with 95% confidence interval. Results: Overall, 91 mChRCC pts were collected. Among these, 63 were treated with TT with a median follow-up of 3 years (range: 0.1-14). Median age at diagnosis was 58 years with a majority of men (62%, n = 39). Most pts had nephrectomy (92%, n = 58). International Metastatic RCC Database Consortium (IMDC...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 4561
Metastatic chromophobe renal cell carcinoma treated with target therapies: A Renal Cross Chanel Group (RCCG) study.
4561 Background: Metastatic Chromophobe renal cell carcinoma (mChRCC) is a rare entity with no specific targeted therapy recommended. We aim to assess the outcome of targeted therapy (TT) in a large cohort of mChRCC patients (pts). Methods: RCCG collected data from 27 centers in France, UK and Italy. Patients’ characteristics, treatments, best response and outcomes were collected. Time to treatment failure (TTF) for first-line treatment was calculated from the initiation of first-line treatment (t0) until failure (progression disease, toxicity, death). Overall survival (OS [95%CI]) was calculated from t0 until death. Survival outcomes were described using Kaplan-Meier method with 95% confidence interval. Results: Overall, 91 mChRCC pts were collected. Among these, 63 were treated with TT with a median follow-up of 3 years (range: 0.1-14). Median age at diagnosis was 58 years with a majority of men (62%, n = 39). Most pts had nephrectomy (92%, n = 58). International Metastatic RCC Database Consortium (IMDC...